Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
253.25
-2.29 (-0.90%)
At close: Jun 15, 2026, 4:00 PM EDT
253.20
-0.05 (-0.02%)
Pre-market: Jun 16, 2026, 5:26 AM EDT
Ligand Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 115.08 | 174.93 | 72.31 | 22.95 | 45.01 | 19.52 |
Short-Term Investments | 664.33 | 558.59 | 183.86 | 147.36 | 166.86 | 321.59 |
Cash & Short-Term Investments | 779.41 | 733.52 | 256.17 | 170.31 | 211.87 | 341.11 |
Cash Growth | 273.10% | 186.35% | 50.41% | -19.62% | -37.89% | -17.04% |
Accounts Receivable | 53.38 | 59.6 | 38.38 | 32.92 | 30.42 | 85.45 |
Inventory | 13.27 | 9.13 | 14.11 | 23.97 | 13.29 | 27.33 |
Other Current Assets | 19.36 | 30.02 | 22.9 | 10.23 | 8.01 | 10.86 |
Total Current Assets | 865.42 | 832.27 | 331.56 | 237.43 | 263.6 | 464.75 |
Net Property, Plant & Equipment | - | - | - | 25.06 | 27.49 | 32.6 |
Other Intangible Assets | 217.34 | 225.44 | 266.65 | 299.61 | 342.46 | 376.69 |
Goodwill | 101.54 | 101.54 | 105.25 | 103.37 | 105.67 | 105.67 |
Long-Term Investments | 119.29 | 167.95 | 10.91 | 49.32 | 3 | - |
Other Long-Term Assets | 228.52 | 233.44 | 227.41 | 72.43 | 20.45 | 317.87 |
Total Assets | 1,532 | 1,561 | 941.77 | 787.22 | 762.67 | 1,298 |
Accounts Payable | 5.26 | 3.24 | 5.23 | 2.43 | 5.31 | 8.4 |
Accrued Expenses | 31.85 | 31.45 | 27.91 | 12.47 | 15.68 | 17.58 |
Current Portion of Long-Term Debt | - | - | - | - | 76.7 | - |
Current Portion of Leases | 1.09 | 1.1 | 1.27 | 0.41 | 0.72 | 1.41 |
Unearned Revenue | - | - | - | 1.22 | 0.36 | 0.65 |
Other Current Liabilities | 2.47 | 1.66 | 2.71 | 0.26 | 0.06 | 13.62 |
Total Current Liabilities | 40.67 | 37.45 | 37.11 | 16.78 | 98.81 | 41.67 |
Long-Term Debt | 446.9 | 446.19 | - | - | - | 320.72 |
Long-Term Leases | 3.99 | 4.2 | 5.82 | 5.76 | 10.34 | 2.26 |
Other Long-Term Liabilities | 43.23 | 55.58 | 68.41 | 63.77 | 56.04 | 111.79 |
Total Long-Term Liabilities | 494.12 | 505.98 | 74.22 | 69.52 | 66.37 | 434.77 |
Total Liabilities | 534.78 | 543.43 | 111.34 | 86.3 | 165.18 | 476.43 |
Preferred Stock | - | - | - | - | - | 0.02 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Additional Paid-in Capital | 397.17 | 400.65 | 337.38 | 198.7 | 147.59 | 372.97 |
Accumulated Other Comprehensive Income | 5.39 | 8.46 | -5.94 | -0.82 | -0.98 | -0.92 |
Retained Earnings | 594.74 | 608.09 | 498.98 | 503.02 | 450.86 | 449.09 |
Total Common Shareholders' Equity | 997.32 | 1,017 | 830.44 | 700.91 | 597.49 | 821.18 |
Shareholders' Equity | 997.32 | 1,017 | 830.44 | 700.91 | 597.49 | 821.16 |
Total Liabilities & Equity | 1,532 | 1,561 | 941.77 | 787.22 | 762.67 | 1,298 |
Total Debt | 451.98 | 451.49 | 7.08 | 6.17 | 87.75 | 324.39 |
Net Cash (Debt) | 327.43 | 282.03 | 249.08 | 164.14 | 124.12 | 16.72 |
Net Cash Growth | 16.10% | 13.23% | 51.75% | 32.24% | 642.28% | - |
Net Cash Per Share | 16.05 | 13.90 | 13.62 | 9.24 | 7.36 | 0.97 |
Book Value | 997.32 | 1,017 | 830.44 | 700.91 | 597.49 | 821.18 |
Book Value Per Share | 48.90 | 50.12 | 45.40 | 39.47 | 35.42 | 47.62 |
Tangible Book Value | 678.44 | 690.23 | 458.54 | 297.94 | 149.36 | 338.81 |
Tangible Book Value Per Share | 33.27 | 34.01 | 25.07 | 16.78 | 8.85 | 19.65 |